These results show that plasma VWF is sufficient to support efficient hemostasis and thrombosis in the mouse, indicating that liver-targeted gene therapy can be considered as a viable treatment alternative for severe VWD. Here, VWF is linked to von Willebrand disease (hereditary or acquired).